Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16510284 | 0.82 | MTNR1A (0.43) | ESR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7073014 | 0.82 | MTNR1A (0.43) | ESR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14761632 | 0.82 | MTNR1A (0.43) | ESR2CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17200595 | 0.78 | ESR2 (0.42) | ESR2HPGDMAPK1HSD17B10HTT | |
| SCHEMBL14137057 | 0.78 | ESR2 (0.42) | ESR2HPGDMAPK1HSD17B10HTT | |
| SCHEMBL13221540 | 0.77 | DRD2 (0.43) | ESR2BRD4 | |
| SCHEMBL7076510 | 0.77 | DRD2 (0.43) | ESR2BRD4 | |
| SCHEMBL7131312 | 0.77 | DRD2 (0.43) | ESR2BRD4 | |
| SCHEMBL7075532 | 0.75 | MAPT (0.43) | ESR2HTTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7075529 | 0.75 | MAPT (0.43) | ESR2HTTCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | HTR5A, HTR3B, HTR1A | CYP4F2 557/4885CYP4A11 1198/4885ESR2 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.